PITTSBURGH, Oct. 12, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it intends to refinance its existing secured credit facility. The proposed $2.25 billion facility is expected to be comprised of a $1 billion revolving credit facility and a $1.25 billion Term Loan A. The facility will have a five year term and include customary terms and covenants. The facility is expected to close in November 2011, subject to market and other customary conditions.
Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry’s broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world’s largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.
SOURCE Mylan Inc.
